Genomic index of sensitivity to endocrine therapy for breast cancer

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages 4111-4119

  Symmans, W Fraser ^a   Hatzis, Christos ^a   Sotiriou, Christos ^a   Andre, Fabrice ^a   Peintinger, Florentia ^a   Regitnig, Peter ^a   Daxenbichler, Guenter ^a   Desmedt, Christine ^a   Domont, Julien ^a   Marth, Christian ^a   Delaloge, Suzette ^a   Bauernhofer, Thomas ^a   Valero, Vicente ^a   Booser, Daniel J ^a   Hortobagyi, Gabriel N ^a   Pusztai, Lajos ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR ALPHA; FLUOROURACIL; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESR1 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; BREAST TUMOR; CANCER STAGING; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; GENOMICS; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957935139     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.4273     Document Type: Article

References (38)

1. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005
2. Winer EP: Optimizing endocrine therapy for breast cancer. J Clin Oncol 23:1609-1610, 2005
3. Swain SM: A step in the right direction. J Clin Oncol 24:3717-3718, 2006
4. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
5. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
6. van 't Veer L, Dai H, van de Vijver M, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
7. Nicholson RI, McClelland RA, Robertson JF, et al: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6:373-387, 1999 (Pubitemid 29459785)
8. Atanaskova N, Keshamouni VG, Krueger JS, et al: MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21:4000-4008, 2002 (Pubitemid 34679241)
9. Johnston SRD, Head J, Pancholi S, et al: Integration of signal transduction inhibitors with endocrine therapy: An approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9:524S-532S, 2003
10. Razandi M, Pedram A, Park ST, et al: Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278:2701-2712, 2003 (Pubitemid 36801351)
11. Shou J, Massarweh S, Osborne CK, et al: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935, 2004 (Pubitemid 38868139)
12. Gruvberger S, Ringner M, Chen Y, et al: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-5984, 2001 (Pubitemid 32762524)
13. Pusztai L, Ayers M, Stec J, et al: Gene expression profiles obtained from fine needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9:2406-2415, 2003 (Pubitemid 36842079)
14. Sotiriou C, Wirapati P, Loi S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272, 2006 (Pubitemid 43264710)
15. Loi S, Haibe-Kains B, Desmedt C, et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239-1246, 2007 (Pubitemid 46640570)
16. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005 (Pubitemid 40260888)
17. Desmedt C, Piette F, Loi S, et al: Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13:3207-3214, 2007 (Pubitemid 46944903)
18. Liedtke C, Hatzis C, Symmans WF, et al: Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 27:3185-3191, 2009
19. Hess KR, Anderson K, Symmans WF, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244, 2006 (Pubitemid 46630780)
20. Gong Y, Yan K, Lin F, et al: Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: A gene-expression profiling study. Lancet Oncol 8:203-211, 2007
21. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999 (Pubitemid 29220854)
22. Kendall G, Gibbons JD: Rank Correlation Methods (ed 5). New York, NY, Oxford University Press, 1990
23. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007 (Pubitemid 46972801)
24. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer-Verlag, 2000
25. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007 (Pubitemid 350013847)
26. Tableman M, Kim JS: Survival Analysis Using S: Analysis of Time-to-Event Data. Boca Raton, FL, Chapman & Hall/CRC, 2004
27. Bramwell VH, Pritchard KI, Tu D, et al: A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA. 12). Ann Oncol 21:283-290, 2010
28. Goldstein LJ, Gray R, Badve S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
29. Albain KS, Barlow WE, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
30. Dowsett M, Cuzick J, Wale C, et al: Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: A TransATAC study. Proc 31st San Antonio Breast Cancer Symposium, San Antonio, TX, September 10-14, 2008 (abstr 53)
31. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007 (Pubitemid 47572635)
32. Andre F, Broglio K, Roche H, et al: Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: Results from a pooled analysis. J Clin Oncol 26:2636-2643, 2008
33. Desmedt C, Haibe-Kains B, Wirapati P, et al: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165, 2008
34. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
35. Symmans WF: A pathologist's perspective on emerging genomic tests for breast cancer. Semin Oncol 34:S4-S9, 2007
36. Fan C, Oh DS, Wessels L, et al: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560-569, 2006 (Pubitemid 44200649)
37. Ellis MJ, Tao Y, Luo J, et al: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380-1388, 2008
38. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360:790-800, 2009